Denator AB, a Gothenburg, Sweden-based develops, markets and sells instruments and consumables to address needs in the life science and clinical research markets, has raised SEK25.5m in its sixth financing.
In conjunction with the funding, Søren Møller, Managing Investment Director at Novo Seeds, has joined the company’s board.
Denator intends to use the funding to further strengthen its expansion plans.
Established in 2004 and led by CEO Olof Sköld, the company develops and markets products that enable scientists to stabilize biological samples, such as tissue sections or cellular biopsies, from the moment of sampling.
Denator has additional research and applications facilities at the Uppsala Science Park, Sweden.
Products are sold directly in major markets such as North America and through a growing network of carefully selected distributors.